World journal of gastrointestinal surgery · 2025
Efficacy of acupoint catgut embedding therapy for phlegm-turbidity and blood-stasis metabolic dysfunction-associated fatty liver disease.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Hu Qiu-Hong, Liu Wen, Yin Hong-Qin, Wang Yun-Fei, Zhang Wen-Kui, Shen Mei-Long
Аннотация
BACKGROUND: No optimal treatment has been established for metabolic dysfunction-associated fatty liver disease with phlegm-turbidity and blood-stasis syndrome (MAFLD-PTBS), highlighting the need for more effective therapeutic approaches.
AIM: To elucidate the clinical effectiveness of acupoint catgut embedding therapy (ACET) for MAFLD-PTBS and preliminarily examine its association with biomarkers, particularly platelet-derived growth factor (PDGF).
METHODS: We retrospectively enrolled 80 patients with MAFLD-PTBS, divided into an ACET group (n = 40) receiving ACET therapy and a control group (n = 40) treated with conventional hepatoprotective and enzyme-lowering oral medications. Therapeutic outcomes were compared between the groups. Changes in body mass index (BMI), abdominal circumference (AC), body weight (BW), total cholesterol (TC), triglycerides (TG), alanine aminotransferase (ALT), aspartate aminotransferase (AST), liver stiffness measurement (LSM), a four-item liver fibrosis panel, and serum concentration of PDGF, transforming growth factor-β1 (TGF-β1), and cytokeratin 18 (CK-18) were assessed before and after treatment.
RESULTS: Significant differences were observed both within group (pre- vs post-treatment) and between group post-intervention for all measured indicators, including BMI, AC, BW, TC, TG, ALT, AST, LSM, liver fibrosis indices, PDGF, TGF-β1, and CK-18 (all P < 0.05).
CONCLUSION: ACET exhibits promising clinical effectiveness for managing MAFLD-PTBS, with effects closely associated with serum concentrations of PDGF, TGF-β1, and CK-18.
AIM: To elucidate the clinical effectiveness of acupoint catgut embedding therapy (ACET) for MAFLD-PTBS and preliminarily examine its association with biomarkers, particularly platelet-derived growth factor (PDGF).
METHODS: We retrospectively enrolled 80 patients with MAFLD-PTBS, divided into an ACET group (n = 40) receiving ACET therapy and a control group (n = 40) treated with conventional hepatoprotective and enzyme-lowering oral medications. Therapeutic outcomes were compared between the groups. Changes in body mass index (BMI), abdominal circumference (AC), body weight (BW), total cholesterol (TC), triglycerides (TG), alanine aminotransferase (ALT), aspartate aminotransferase (AST), liver stiffness measurement (LSM), a four-item liver fibrosis panel, and serum concentration of PDGF, transforming growth factor-β1 (TGF-β1), and cytokeratin 18 (CK-18) were assessed before and after treatment.
RESULTS: Significant differences were observed both within group (pre- vs post-treatment) and between group post-intervention for all measured indicators, including BMI, AC, BW, TC, TG, ALT, AST, LSM, liver fibrosis indices, PDGF, TGF-β1, and CK-18 (all P < 0.05).
CONCLUSION: ACET exhibits promising clinical effectiveness for managing MAFLD-PTBS, with effects closely associated with serum concentrations of PDGF, TGF-β1, and CK-18.